#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's

Data Readoutnegativeamylin analogNegative

AI Analysis

Summary

Zealand and Roche's amylin analog demonstrated disappointing weight loss results in Phase 2 obesity trial data presented at EASD26, trailing Eli Lilly's competing therapy.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Weight loss was disappointing compared to Lilly's competitor therapy

Importance:6/10

Sentiment:

-0.60

obesityweight lossamylin analogPhase 2 dataEASD conferencecompetitive comparison

Related Companies

$ZEAL $RHHBY

Read the original article

Published by Endpoints News on September 29, 2026 10:01 PM

Read Original